Cargando…

Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity

Retigabine is unique among anticonvulsant drugs by targeting the neuronal M-channel, which is composed of K(V)7.2/K(V)7.3 and contributes to the negative neuronal resting membrane potential. Unfortunately, retigabine causes adverse effects, which limits its clinical use. Adverse effects may be reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Larsson, Johan E., Karlsson, Urban, Wu, Xiongyu, Liin, Sara I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398146/
https://www.ncbi.nlm.nih.gov/pubmed/32365171
http://dx.doi.org/10.1085/jgp.202012576
_version_ 1783565905495588864
author Larsson, Johan E.
Karlsson, Urban
Wu, Xiongyu
Liin, Sara I.
author_facet Larsson, Johan E.
Karlsson, Urban
Wu, Xiongyu
Liin, Sara I.
author_sort Larsson, Johan E.
collection PubMed
description Retigabine is unique among anticonvulsant drugs by targeting the neuronal M-channel, which is composed of K(V)7.2/K(V)7.3 and contributes to the negative neuronal resting membrane potential. Unfortunately, retigabine causes adverse effects, which limits its clinical use. Adverse effects may be reduced by developing M-channel activators with improved K(V)7 subtype selectivity. The aim of this study was to evaluate the prospect of endocannabinoids as M-channel activators, either in isolation or combined with retigabine. Human K(V)7 channels were expressed in Xenopus laevis oocytes. The effect of extracellular application of compounds with different properties was studied using two-electrode voltage clamp electrophysiology. Site-directed mutagenesis was used to construct channels with mutated residues to aid in the mechanistic understanding of these effects. We find that arachidonoyl-L-serine (ARA-S), a weak endocannabinoid, potently activates the human M-channel expressed in Xenopus oocytes. Importantly, we show that ARA-S activates the M-channel via a different mechanism and displays a different K(V)7 subtype selectivity compared with retigabine. We demonstrate that coapplication of ARA-S and retigabine at low concentrations retains the effect on the M-channel while limiting effects on other K(V)7 subtypes. Our findings suggest that improved K(V)7 subtype selectivity of M-channel activators can be achieved through strategically combining compounds with different subtype selectivity.
format Online
Article
Text
id pubmed-7398146
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-73981462021-02-03 Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity Larsson, Johan E. Karlsson, Urban Wu, Xiongyu Liin, Sara I. J Gen Physiol Article Retigabine is unique among anticonvulsant drugs by targeting the neuronal M-channel, which is composed of K(V)7.2/K(V)7.3 and contributes to the negative neuronal resting membrane potential. Unfortunately, retigabine causes adverse effects, which limits its clinical use. Adverse effects may be reduced by developing M-channel activators with improved K(V)7 subtype selectivity. The aim of this study was to evaluate the prospect of endocannabinoids as M-channel activators, either in isolation or combined with retigabine. Human K(V)7 channels were expressed in Xenopus laevis oocytes. The effect of extracellular application of compounds with different properties was studied using two-electrode voltage clamp electrophysiology. Site-directed mutagenesis was used to construct channels with mutated residues to aid in the mechanistic understanding of these effects. We find that arachidonoyl-L-serine (ARA-S), a weak endocannabinoid, potently activates the human M-channel expressed in Xenopus oocytes. Importantly, we show that ARA-S activates the M-channel via a different mechanism and displays a different K(V)7 subtype selectivity compared with retigabine. We demonstrate that coapplication of ARA-S and retigabine at low concentrations retains the effect on the M-channel while limiting effects on other K(V)7 subtypes. Our findings suggest that improved K(V)7 subtype selectivity of M-channel activators can be achieved through strategically combining compounds with different subtype selectivity. Rockefeller University Press 2020-05-04 /pmc/articles/PMC7398146/ /pubmed/32365171 http://dx.doi.org/10.1085/jgp.202012576 Text en © 2020 Larsson et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Article
Larsson, Johan E.
Karlsson, Urban
Wu, Xiongyu
Liin, Sara I.
Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity
title Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity
title_full Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity
title_fullStr Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity
title_full_unstemmed Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity
title_short Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity
title_sort combining endocannabinoids with retigabine for enhanced m-channel effect and improved k(v)7 subtype selectivity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398146/
https://www.ncbi.nlm.nih.gov/pubmed/32365171
http://dx.doi.org/10.1085/jgp.202012576
work_keys_str_mv AT larssonjohane combiningendocannabinoidswithretigabineforenhancedmchanneleffectandimprovedkv7subtypeselectivity
AT karlssonurban combiningendocannabinoidswithretigabineforenhancedmchanneleffectandimprovedkv7subtypeselectivity
AT wuxiongyu combiningendocannabinoidswithretigabineforenhancedmchanneleffectandimprovedkv7subtypeselectivity
AT liinsarai combiningendocannabinoidswithretigabineforenhancedmchanneleffectandimprovedkv7subtypeselectivity